# Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

> **NCT00831233** · PHASE3 · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Goserelin
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00831233
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-07
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Poor recruitment due to rare targeted population
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00831233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00831233, "Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00831233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*